

## Correction: *Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial*

---

Haberman RH, MacFarlane KA, Catron S, *et al.* Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. *BMJ Open* 2022;12:e063650. doi: 10.1136/bmjopen-2022-063650

The authors want to alert the readers that a typographical error noticed in the abstract and Box 1, has now been corrected.

In the abstract, an end parenthesis “)” was added to separate the FDA acronym from the rest of the sentence.

In Box 1, slight change in wording of the two coprimary endpoints as well as adding two secondary endpoints to align with the PAMPA trial’s posting on clinicaltrial.gov.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

*BMJ Open* 2023;13:e063650corr1. doi:10.1136/bmjopen-2022-063650corr1

